Biotech Hangout
Episode 122 - November 22, 2024
This episode isn’t summarized yet
Create a free account and summarize it. In a few minutes you’ll have the key takeaways and a section-by-section summary.
Show notes
On this episode of Biotech Hangout, Eric Schmidt, Bruce Booth, Yaron Werber, Tim Opler and Mike Yee begin the show discussing the highlights from the Jefferies Healthcare Conference before taking a look at public investor sentiment this week. The discussion turns to Atlas Venture’s 2024 Year in Review and transitions into the emerging themes for 2025. The hosts also recap ACR Convergence including Amgen’s Phase 3 data as well as data from cell therapies for SLE, SSC, IMNM. The group also discuss lipid readouts from Eli Lilly, Silence Therapeutics and NewAmsterdam Pharma. Other topics covered include the Incyte and Escient deal collapse, Kura Oncology’s pact with Kyowa Kirin, and perspectives on Trump’s nomination of Dr. Mehmet Oz to lead the CMS. This episode aired on November 22, 2024.